UHS Q2 Revenue Beats, But Guidance Cut and Facility Terminations Weigh
UHS sits 24% above its 52-week low of $140.08 on light trading volume (0.4× avg).
Summary
UHS beat Q2 revenue estimates but cut full-year EPS guidance. Two behavioral health facilities lost licenses, and the Cumberland litigation trial looms. The company is expanding via the Talkspace acquisition and a new Irish deal.
Key Events · Earnings and Guidance · UHS
-
Q2 Revenue Beat, Guidance Cut
Q2 net revenues of $4.64B beat consensus of $4.58B, but full-year adjusted EPS guidance was lowered to $11.85-$12.65 from $12.20-$13.00, reflecting headwinds from facility terminations and higher costs.
-
Facility Terminations Hit Behavioral Segment
Laurel Ridge Treatment Center (330 beds) lost Medicare/Medicaid certification, and Provo Canyon School's license was revoked by Utah DHHS. Combined, these facilities generated ~$25M in pre-tax income in 2025.
-
Cumberland Litigation Trial Set for August 2026
A consolidated trial for three plaintiffs in the Cumberland sexual abuse litigation is scheduled for August 2026, with 43 additional plaintiffs pending. The company has $143M of remaining insurance coverage for the 2020 policy year.
-
Talkspace Acquisition on Track for Q3 Close
The $835M acquisition of virtual behavioral health company Talkspace received stockholder approval and is expected to close in Q3 2026, financed by a new $400M delayed draw term loan.
Analysis · UHS · Industrial Applications And Services
Universal Health Services posted strong Q2 revenue of $4.64 billion, beating consensus, but lowered its full-year adjusted EPS guidance to $11.85-$12.65 from $12.20-$13.00. The quarter was marred by the termination of Laurel Ridge Treatment Center from Medicare/Medicaid and the license revocation of Provo Canyon School, which together will pressure future earnings. The company also faces ongoing litigation headwinds from the Cumberland matter, with a new trial set for August 2026. On the strategic front, UHS is moving forward with the $835 million Talkspace acquisition and a $188 million Irish behavioral health deal, while adding a $700 million credit facility to manage near-term debt maturities. The mixed quarter — revenue strength offset by operational and legal setbacks — keeps the stock in a holding pattern.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UHS was trading at $173.54 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.5B. The 52-week trading range was $140.08 to $246.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.